Yashwant M. Deo

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

Frank H. Valone, Peter A. Kaufman, Paul M. Guyre et al. · Journal of Clinical Oncology · 1995 · 183 citations

FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy

Thomas Valerius, Bernhard Stockmeyer, Annemiek B. van Spriel et al. · Blood · 1997 · 122 citations · Full text

Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.

Bernhard Stockmeyer, Thomas Valerius, Roland Repp et al. · PubMed · 1997 · 96 citations

Breast Oncology, Immunology, Immunoediting +18

Practical Considerations in Operation and Scale-up of Spin-Filter Based Bioreactors for Monoclonal Antibody Production

Yashwant M. Deo, Mina D. Mahadevan, Rainer Fuchs · Biotechnology Progress · 1996 · 91 citations

HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor

David Elsässer, Thomas Valerius, Roland Repp et al. · Blood · 1996 · 88 citations · Full text